MarketPeel
Insider Trading Intelligence
Pricing
…
MN

Maximo F. Nougues

PBYI
CHIEF FINANCIAL OFFICER · PUMA BIOTECHNOLOGY, INC. · CIK 0001758507
FILING MIX · LIFETIME29%/71%
BUYS
14
SELLS
35
TOTAL VALUE
$459.3K
COMPANIES
1
ACTIVE SINCE
Feb 2020
HOLDINGS NOW
230,637
AVG SELL PX
$4.42
TRADE KIND
SHOWING 49 / 49
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
33 backtested trades · 8 horizons · 8 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Maximo F. Nougues, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d33+45.45%+3.61%-0.06%+3.66%+2.54%1.33
14d33+54.55%+2.99%+0.24%+2.75%-4.13%0.91
30d33+51.52%+1.42%+0.83%+0.58%-3.63%0.14
60d33+57.58%+0.06%+1.07%-1.01%-7.55%-0.18
90d33+66.67%-0.60%+1.78%-2.38%-7.21%-0.37
180d33+57.58%-3.23%+3.86%-7.09%-6.86%-0.81
1y33(2 pending)+48.39%-2.14%+6.69%-8.83%-12.62%-0.79
2y33(6 pending)+51.85%+4.17%+22.29%-18.12%-53.16%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
PBYI · 230,637 shares · as of Jul 6, 2026
060,006120,012180,017240,023202120222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2020
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
2026
FLOW · 14 buys / 35 sellsCOVERAGE · 27 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
PBYI
PUMA BIOTECHNOLOGY, INC.
SALE10b5-1
10b5-1 plan
9,386$8.26$77.6K230,637Jul 6, 2026Jul 8, 2026 ↗View →
PBYI
PUMA BIOTECHNOLOGY, INC.
PURCHASEGRANT
Stock grant
66,541——66,541Feb 18, 2026Feb 20, 2026 ↗View →
PBYI
PUMA BIOTECHNOLOGY, INC.
PURCHASEGRANT
Stock grant
46,739——240,023Feb 18, 2026Feb 20, 2026 ↗View →
PBYI
PUMA BIOTECHNOLOGY, INC.
SALE10b5-1
10b5-1 plan
6,405$5.88$37.7K193,284Jan 7, 2026Jan 8, 2026 ↗View →
PBYI
PUMA BIOTECHNOLOGY, INC.
SALE10b5-1
10b5-1 plan
4,540$5.84$26.5K199,689Jan 6, 2026Jan 8, 2026 ↗View →
PBYI
PUMA BIOTECHNOLOGY, INC.
SALE10b5-1
10b5-1 plan
3,935$3.54$13.9K204,229Jul 9, 2025Jul 10, 2025 ↗View →
PBYI
PUMA BIOTECHNOLOGY, INC.
SALE10b5-1
10b5-1 plan
5,587$3.53$19.7K208,164Jul 8, 2025Jul 10, 2025 ↗View →
PBYI
PUMA BIOTECHNOLOGY, INC.
PURCHASEGRANT
Stock grant
61,456——213,751Feb 7, 2025Feb 11, 2025 ↗View →
PBYI
PUMA BIOTECHNOLOGY, INC.
PURCHASEGRANT
Stock grant
85,067——85,067Feb 7, 2025Feb 11, 2025 ↗View →
PBYI
PUMA BIOTECHNOLOGY, INC.
SALE10b5-1
10b5-1 plan
10,227$3.15$32.2K152,295Jan 2, 2025Jan 3, 2025 ↗View →
PBYI
PUMA BIOTECHNOLOGY, INC.
SALE10b5-1
10b5-1 plan
4,156$3.70$15.4K162,522Jul 17, 2024Jul 18, 2024 ↗View →
PBYI
PUMA BIOTECHNOLOGY, INC.
SALE10b5-1
10b5-1 plan
5,295$3.27$17.3K166,678Jul 2, 2024Jul 2, 2024 ↗View →
PBYI
PUMA BIOTECHNOLOGY, INC.
PURCHASEGRANT
Stock grant
43,307——171,973Feb 12, 2024Feb 14, 2024 ↗View →
PBYI
PUMA BIOTECHNOLOGY, INC.
PURCHASEGRANT
Stock grant
59,946——59,946Feb 12, 2024Feb 14, 2024 ↗View →
PBYI
PUMA BIOTECHNOLOGY, INC.
SALE10b5-1
10b5-1 plan
15,682$4.49$70.3K128,666Jan 3, 2024Jan 5, 2024 ↗View →
PBYI
PUMA BIOTECHNOLOGY, INC.
PURCHASEGRANT
Stock grant
58,601——159,028Feb 10, 2023Feb 14, 2023 ↗View →
PBYI
PUMA BIOTECHNOLOGY, INC.
PURCHASEGRANT
Stock grant
81,399——81,399Feb 10, 2023Feb 14, 2023 ↗View →
PBYI
PUMA BIOTECHNOLOGY, INC.
SALE
Chief Financial Officer
10,499$4.18$43.9K100,427Jan 3, 2023Jan 5, 2023 ↗View →
PBYI
PUMA BIOTECHNOLOGY, INC.
SALE
Chief Financial Officer
159$4.50$715110,926Dec 2, 2022Dec 6, 2022 ↗View →
PBYI
PUMA BIOTECHNOLOGY, INC.
SALE
Chief Financial Officer
163$2.25$367111,085Nov 2, 2022Nov 4, 2022 ↗View →
PBYI
PUMA BIOTECHNOLOGY, INC.
SALE
Chief Financial Officer
165$2.34$385111,248Oct 3, 2022Oct 5, 2022 ↗View →
PBYI
PUMA BIOTECHNOLOGY, INC.
SALE
Chief Financial Officer
164$2.59$425111,413Sep 2, 2022Sep 7, 2022 ↗View →
PBYI
PUMA BIOTECHNOLOGY, INC.
SALE
Chief Financial Officer
161$2.89$465111,577Aug 2, 2022Aug 4, 2022 ↗View →
PBYI
PUMA BIOTECHNOLOGY, INC.
SALE
Chief Financial Officer
5,835$2.63$15.4K64,625Jul 5, 2022Jul 7, 2022 ↗View →
PBYI
PUMA BIOTECHNOLOGY, INC.
SALE
Chief Financial Officer
9,328$2.63$24.5K111,738Jul 5, 2022Aug 4, 2022 ↗View →
PBYI
PUMA BIOTECHNOLOGY, INC.
SALE
Chief Financial Officer
162$1.92$311121,066Jun 2, 2022Jun 6, 2022 ↗View →
PBYI
PUMA BIOTECHNOLOGY, INC.
SALE
Chief Financial Officer
165$2.34$386121,228May 3, 2022May 4, 2022 ↗View →
PBYI
PUMA BIOTECHNOLOGY, INC.
SALE
Chief Financial Officer
206$3.08$634121,393Apr 4, 2022Apr 5, 2022 ↗View →
PBYI
PUMA BIOTECHNOLOGY, INC.
PURCHASEGRANT
Stock grant
62,176——121,599Mar 3, 2022Mar 14, 2022 ↗View →
PBYI
PUMA BIOTECHNOLOGY, INC.
PURCHASEGRANT
Stock grant
88,824——88,824Mar 3, 2022Mar 14, 2022 ↗View →
PBYI
PUMA BIOTECHNOLOGY, INC.
SALE
Chief Financial Officer
169$2.26$38259,423Mar 2, 2022Mar 4, 2022 ↗View →
PBYI
PUMA BIOTECHNOLOGY, INC.
SALE
Chief Financial Officer
199$2.48$49459,592Feb 2, 2022Feb 3, 2022 ↗View →
PBYI
PUMA BIOTECHNOLOGY, INC.
SALE
Chief Financial Officer
7,484$3.19$23.9K59,791Jan 3, 2022Jan 5, 2022 ↗View →
PBYI
PUMA BIOTECHNOLOGY, INC.
SALE
Chief Financial Officer
162$2.95$47867,275Dec 2, 2021Dec 6, 2021 ↗View →
PBYI
PUMA BIOTECHNOLOGY, INC.
SALE
Chief Financial Officer
156$5.67$88567,437Nov 2, 2021Nov 3, 2021 ↗View →
PBYI
PUMA BIOTECHNOLOGY, INC.
SALE
Chief Financial Officer
161$6.20$99867,593Oct 4, 2021Oct 6, 2021 ↗View →
PBYI
PUMA BIOTECHNOLOGY, INC.
SALE
Chief Financial Officer
155$7.51$1.2K67,754Sep 2, 2021Sep 3, 2021 ↗View →
PBYI
PUMA BIOTECHNOLOGY, INC.
SALE
Chief Financial Officer
154$7.54$1.2K67,909Aug 2, 2021Aug 3, 2021 ↗View →
PBYI
PUMA BIOTECHNOLOGY, INC.
SALE
Chief Financial Officer
155$9.26$1.4K68,063Jul 2, 2021Jul 6, 2021 ↗View →
PBYI
PUMA BIOTECHNOLOGY, INC.
SALE
Chief Financial Officer
152$10.74$1.6K68,218Jun 2, 2021Jun 4, 2021 ↗View →
PBYI
PUMA BIOTECHNOLOGY, INC.
SALE
Chief Financial Officer
152$9.91$1.5K68,370May 3, 2021May 5, 2021 ↗View →
PBYI
PUMA BIOTECHNOLOGY, INC.
SALE
Chief Financial Officer
155$9.80$1.5K68,522Apr 5, 2021Apr 6, 2021 ↗View →
PBYI
PUMA BIOTECHNOLOGY, INC.
SALE
Chief Financial Officer
154$10.14$1.6K68,677Mar 2, 2021Mar 4, 2021 ↗View →
PBYI
PUMA BIOTECHNOLOGY, INC.
PURCHASEGRANT
Stock grant
78,209——78,209Feb 17, 2021Feb 19, 2021 ↗View →
PBYI
PUMA BIOTECHNOLOGY, INC.
PURCHASEGRANT
Stock grant
55,595——68,831Feb 17, 2021Feb 19, 2021 ↗View →
PBYI
PUMA BIOTECHNOLOGY, INC.
SALE
Chief Financial Officer
179$12.26$2.2K13,236Feb 2, 2021Feb 4, 2021 ↗View →
PBYI
PUMA BIOTECHNOLOGY, INC.
SALE
Chief Financial Officer
2,145$10.22$21.9K13,415Jan 4, 2021Jan 6, 2021 ↗View →
PBYI
PUMA BIOTECHNOLOGY, INC.
PURCHASEGRANT
Stock grant
15,567——15,567Feb 11, 2020Feb 13, 2020 ↗View →
PBYI
PUMA BIOTECHNOLOGY, INC.
PURCHASEGRANT
Stock grant
15,560——15,560Feb 11, 2020Feb 13, 2020 ↗View →
Other insiders · PBYI
Loading peer insiders…
About this filer
CIK 0001758507
ROLE
Chief Financial Officer
PRIMARY
PBYI
COMPANIES
1
ACTIVE SINCE
Feb 2020
MARKETPEEL · /INSIDER/0001758507DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback